July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Short-Term effects of Ranibizumab on Diabetic Retinopathy Severity and Progression in the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study.
Author Affiliations & Notes
  • Muhammad Hassan
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Mohammad Ali Sadiq
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Muhammad Sohail Halim
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Rubbia Afridi
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Nam V Nguyen
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
    Ocular Imaging Research and Reading Center, Menlo Park, California, United States
  • Yasir Jamal Sepah
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
    Ocular Imaging Research and Reading Center, Menlo Park, California, United States
  • Footnotes
    Commercial Relationships   Muhammad Hassan, None; Mohammad Sadiq, None; Muhammad Halim, None; Rubbia Afridi, None; Nam Nguyen, None; Yasir Sepah, Genentech (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1909. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Muhammad Hassan, Mohammad Ali Sadiq, Muhammad Sohail Halim, Rubbia Afridi, Nam V Nguyen, Yasir Jamal Sepah; Short-Term effects of Ranibizumab on Diabetic Retinopathy Severity and Progression in the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1909.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the short-term effects of two doses of Ranibizumab (0.5mg and 2.0mg) on diabetic retinopathy (DR) severity in patients with diabetic macular edema (DME).

Methods : In the READ-3 study, patients with DME were stratified into two groups to receive either 0.5mg or 2.0mg monthly intravitreal ranibizumab until month 6, followed by pro-re-nata dosing until month 24. Seven field fundus photographs were evaluated utilizing a 9-step ETDRS diabetic retinopathy (DR) severity scale, to assess DR severity at baseline, month 3 and month 6 by a centralized reading center. Chi-sqaure and logistic regression was utilized to assess differences in proportion of subjects demonstrating change in DR severity at month 3 and month 6.

Results : Out of 152 eyes (152 patients) randomized in the READ-3 study, 91 eyes (91 patients) fulfilled the inclusion criteria for the index study. Thirty-nine eyes in the 0.5mg group and 24 eyes in 2.0mg group with the potential for improvement in the DR severity score were analyzed. Twenty-eight eyes (44.4%; 18 in 0.5mg and 10 in 2.0mg) had a prior history of PRP with baseline DR severity score 60. The median ETDRS DR severity score improved from 4 (moderate NPDR) to 3 (mild NPDR) at month 3 and was maintained at month 6 in both study groups. The proportion of patients with DR severity score of mild or better increased at month 3 (0.5mg:32.4% and 2.0mg:36.4%) and month 6 (0.5mg:41% and 2.0mg:50%) from baseline (0.5mg: 12.8% and 2.0mg: 4.2%) (Figure 1). 22.9% of eyes (groups combined) demonstrated a ≥2-step reduction in the ETDRS DR severity scale (0.5mg: 33.3% and 2.0mg:7.1%), at month 6 (Figure 2). The difference between the groups was not significant (p=0.071). Worsening of the DR severity was not demonstrated by any of the study subjects.

Conclusions : Intravitreal ranibizumab has a role in stopping the progression of DR severity in patient with DME starting as early as 3 to 6 months. 2.0 mg ranibizumab did not demonstrate any additional benefit over 0.5mg ranibizumab in improving DR severity.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Figure 1. Proportion of Subjects with ETDRS Severity Score of Mild or Better

Figure 1. Proportion of Subjects with ETDRS Severity Score of Mild or Better

 

Figure 2. Percentage of Patients with ≥2 Step Reduction in DR Severity Score

Figure 2. Percentage of Patients with ≥2 Step Reduction in DR Severity Score

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×